Free tool
FAERS Monitor: Tindamax
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021682 or its brand name (Tindamax, Tinidazole). Reports on generic versions are filed under their own applications.
Reports
435
Serious
314
72% of reports
Hospitalization
127
Death reported
20
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective33
- nausea28
- off label use26
- pruritus26
- headache25
- diarrhoea22
- vomiting22
- pyrexia21
- rash21
- anxiety20
- neuropathy peripheral19
- paraesthesia19
- pain17
- dizziness15
- dyspnoea13
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 8 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 5 |
| 2009 | 10 |
| 2010 | 11 |
| 2011 | 16 |
| 2012 | 18 |
| 2013 | 18 |
| 2014 | 25 |
| 2015 | 21 |
| 2016 | 31 |
| 2017 | 18 |
| 2018 | 27 |
| 2019 | 38 |
| 2020 | 49 |
| 2021 | 31 |
| 2022 | 24 |
| 2023 | 34 |
| 2024 | 12 |
| 2025 | 24 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,724 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neuropathy peripheralSignal | 19 | 9.7 | 6.2 | 140 |
| paraesthesiaSignal | 19 | 5.8 | 3.8 | 72 |
| anxietySignal | 20 | 3.4 | 2.2 | 32 |
| pruritusSignal | 26 | 3.3 | 2.3 | 39 |
| pyrexiaSignal | 21 | 2.9 | 1.9 | 25 |
| rashSignal | 21 | 2.3 | 1.5 | 15 |
| vomitingSignal | 22 | 2.3 | 1.5 | 15 |
| headache | 25 | 1.9 | 1.3 | 11 |
| nausea | 28 | 1.7 | 1.2 | 8 |
| diarrhoea | 22 | 1.6 | 1.1 | 5 |
| dizziness | 15 | 1.5 | 0.9 | 2 |
| off label use | 26 | 1.4 | 1.0 | 3 |
| pain | 17 | 1.3 | 0.8 | 1 |
| drug ineffective | 33 | 1.2 | 0.9 | 1 |
| dyspnoea | 13 | 1.1 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.